ERBB2 and breast cancer: Although no confirmed complete or partial responses were observed during the course of the study, tumor shrinkage of more than 30% (unconfirmed partial response) was observed in one patient with HER2+ breast cancer (40 mg/kg group), and tumor shrinkage was also observed in three of the other five patients with HER2+ breast cancer across all doses.